Eisai Co (TSE:4523) Debt-to-Asset : 0.13 (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Eisai Co Debt-to-Asset?

Eisai Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円31,502 Mil. Eisai Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円134,758 Mil. Eisai Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was 円1,311,234 Mil. Eisai Co's debt to asset for the quarter that ended in Dec. 2023 was 0.13.

Eisai Co Debt-to-Asset Historical Data

The historical data trend for Eisai Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Debt-to-Asset Chart

Eisai Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Get a 7-Day Free Trial

0.13

0.09

0.08

0.10

Eisai Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.12	0.10	0.10	0.10	0.13

Competitive Comparison of Eisai Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eisai Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Eisai Co's Debt-to-Asset falls into.

Eisai Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Eisai Co's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(41201	+	84904)	/	1263350
	=	0.10

Eisai Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(31502	+	134758)	/	1311234
	=	0.13

Eisai Co (TSE:4523) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Eisai Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Eisai Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Eisai Co (TSE:4523) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ESAIY:USA ESALF:USA EII:Germany

Address

4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088

Website

http://www.eisai.co.jp

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines